

M-F  
DT05 R&D PCT/PTO 24 SEP 2002  
PCT



SBCD  
#

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of

: Confirmation No. 6799

Seishi KATO et al.

: Docket No. 2002-0400A

Serial No. 10/088,859

: Group Art Unit Not Yet Assigned

Filed May 29, 2002

: Examiner Not Yet Assigned

A METHOD FOR PRODUCING AN  
ANTIBODY BY GENE IMMUNIZATION

RESPONSE

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE FOR DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

Assistant Commissioner for Patents,  
Washington, D.C. 20231

Sir:

Responsive to the Notice dated September 13, 2002, there is submitted herewith, a copy of the Sequence Listing in computer readable form as required by 37 CFR 1.821(e).

Applicants note that the submitted computer readable Sequence Listing is the same as that previously submitted with Applicants' response of June 28, 2002. Applicants presume that the diskette was lost by the Patent Office and have thus submitted another computer readable copy.

Applicants also note that the enclosed computer readable Sequence Listing contains the identical sequences appearing in the original application papers and thus no new matter has been added. Further, it should also be noted that the content of the present computer readable copy is the same as that of the paper copy submitted with our response of June 28, 2002.

A copy of the Notice is also attached as required.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Seishi KATO et al.

By: \_\_\_\_\_

Lee Cheng

Registration No. 40,949

Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 24, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/088,859	Kato Seishi	2002-0400 A

000513

WENDEROTH, LIND & PONACK, L.L.P.  
 2033 K STREET N. W.  
 SUITE 800  
 WASHINGTON, DC 20006-1021

INTERNATIONAL APPLICATION NO.

PCT/JP01/06371

I.A. FILING DATE

07/24/2001

PRIORITY DATE

07/24/2000

CONFIRMATION NO. 6799

371 FORMALITIES LETTER



\*OC000000008785987\*

Date Mailed: 09/13/2002

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration

RECEIVED

SEP 18 2002

WENDEROTH, LIND &amp; PONACK

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f),

1.821(g), 1.825(b) or 1.825(d).

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 305-3736

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/088,859	PCT/JP01/06371	2002-0400 A

FORM PCT/DO/EO/916 (371 Formalities Notice)